JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 3. P. 82–87
Yu.D. Udalov1, A.S. Samoylov2, L.A. Danilova1, E.L. Slobina1, E.M. Stepanyuchenko1,
I.A. Bogomolova1, N.V. Kashentseva1, V.A. Kiselev1, A.A. Vanchugov1,
V.A. Andreev1, E.A. Stepanov1
Modern Treatment of Non-Small Cell Lung Cancer with Intracerebral Metastases
and Extracranial Metastatic Affection of Liver, Mediastinal Lymph Nodes, Skeletal Bones.
Clinical Observation
1Federal High-Technology Centre for Medical Radiology, Dimitrovgrad, Russia
2A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Ludmila Alekseevna Danilova: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Introduction: The article covers issues related to modern methods of treatment of non-small cell lung cancer (NSCLC) with multiple synchronous metastases in brain, liver, mediastinal lymph nodes, skeletal bones and describes a clinical case of modern effective treatment and long-term follow-up of a patient with advanced NSCLC and extra- and intracranial metastatic spread.
Purpose: Evaluation of modern methods of special antitumor treatment and their application in clinical practice for the treatment of metastatic NSCLC.
Material and methods: Modern methods of proton and photon radiation therapy, targeted therapy are considered.
Results: The use of modern methods of special antitumor therapy has increased the overall and relapse-free survival rate of patients with multiple metastases of NSCLC in brain, liver, mediastinal lymph nodes, skeletal bones reducing the need for additional interventions. This is confirmed by a long-term follow-up after modern effective antitumor treatment of a patient with advanced NSCLC and synchronous progression in the form of extra- and intracranial metastatic spread. The patient has been alive for more than 2 years from the moment of progression with an estimated life expectancy of 4–5 months.
Conclusion: Modern methods of special antitumor therapy can increase the survival rate of patients with multiple synchronous NSCLC metastases in brain, liver, mediastinal lymph nodes, skeletal bones without significant deterioration in their quality of life.
Key words:non-small cell lung cancer, intracerebral (intracranial) metastases, extracranial metastases, targeted therapy, proton and photon radiation therapy
For citation: Udalov YuD, Samoylov AS, Danilova LA, Slobina EL, Stepanyuchenko EM, Bogomolova IA, Kashentseva NV, Kiselev VA, Vanchugov AA, Andreev VA, Stepanov EA. Modern Treatment of Non-Small Cell Lung Cancer with Intracerebral Metastases and Extracranial Metastatic Affection of Liver, Mediastinal Lymph Nodes, Skeletal Bones. Clinical Observation. Medical Radiology and Radiation Safety. 2021;66(3):82-87.
DOI: 10.12737/1024-6177-2021-66-3-82-87
References
- Wen PY, et al. in De Vita VT Jr, et al. (eds.) Cancer: Principles & Practice of Oncology. 2005:2656-70.
- Larson D, Rubenstein JM, McDermott, et al. Treatment of Metastatic Cancer: Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2004: 2323-98.
- Pollock BE, Brown PD, Foote RL, et al. Properly Selected Patients with Multiple Brain Metastases May Benefit From Aggressive Treatment of Their Intracranial Disease. J Neurooncol. 2003;Jan;61;1:73-80. DOI: 10.1023/a:1021262218151.
- Gaspar L, Scott C, Rotman M et al. Recursive Partitioning Analysis (RPA) of Prognostic Factors in three Radiation Therapy Oncology Group (RTOG) Brain Metastases Trials. Int J Radiat Oncol Biol Phys. 1997 Mar.1;37(4):745-51. DOI: 10.1016/j.ctrv.2004.05.001.
- Kaprin AD, Starinskiy VV, Shakhzadova AO. The state of Cancer Care for the Population of Russia in 2019. Moscow, P.A.Herzen MNIOI Publ., 2020. 239 p. (In Russian).
- Weltman E, Salvajoli J., Brandt R, et al. Radiosurgery for Brain Metastases: a Score Index for Predicting Prognosis. Int J Radiat Oncol Biol Phys. 2000;46:1155-61. DOI: 10.1016/S0360-3016(99)00549-0.
- Sperduto P, Berkey B, Gaspar L, et al. A New Prognostic Index and Comparison to Three Other Indices for Patients with Brain Metastases: an Analysis of 1,960 Patients in the RTOG Database. Int J Radiat Oncol Biol Phys. 2008;70:510-14. DOI: 10.1016/j.ijrobp.2007.06.074.
- Granone P, Margaritora S, D'Andrilli A, et al. Non-small Cell Lung Cancer with Single Brain Metastasis: the Role of Surgical Treatment. European Journal of Cardio-Thoracic Surgery. 2001 August;20(2):361-66. DOI:10.1016/S1010-7940(01)00744-8.
- Barton R. Inoperable Brain Metastases From Non-Small Cell Lung Cancer: What Part Does Whole Brain Radiotherapy Play in Standard Treatment? 2007. DOI:org/10.1136/thx.2007.086215.
- National Comprehensive Cancer Network. Central Nervous System Cancers. NCCN Guidelines. J Natl Compr Canc Netw. 2020. Sep 11. Version 3.
- Antuña AR, Vega MA, Sanchez CR, Fernandez VM. Brain Metastases of Non-Small Cell Lung Cancer: Prognostic Factors in Patients with Surgical Resection. J Neurol Surg A Cent Eur Neurosurg. 2018;Mar;79;2:101-7. DOI: 10.1055/s-0037-1601874.
- Klimanov VA, Samoylov AS, Gadzhinov AE, Peshkin YaA. Physics of Proton Therapy Treatment Planning. Medical Radiology and Radiation Safety. 2019;64(2):23-32. DOI: 10.12737/article_5ca5e2677a1a06.60363700.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.